New combo therapy targets rare, aggressive kidney cancer
NCT ID NCT05347212
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether two immunotherapy drugs, nivolumab and relatlimab, can shrink or control a rare and aggressive kidney cancer called renal medullary carcinoma (RMC). The trial includes 30 adults whose cancer has spread or cannot be removed by surgery. The goal is to see how many patients respond to the treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- New hope for rare cervical cancer: drug trial targets tumor control
- New drug cocktail targets rare, aggressive kidney cancer
- Immunotherapy combo tested for rare kidney cancer, but trial stopped early
- Scientists launch Largest-Ever study of rare bladder and genital cancers
- New combo therapy targets rare, aggressive kidney tumors